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ABSTRACT
Objective: To determine Mycoplasma genitalium
infection and correlates among young women
undergoing population-based screening or clinic-based
testing for Chlamydia infection.
Design: Cross-sectional study.
Setting: National Chlamydia Screening Programme
(NCSP) and two London sexually transmitted infection
(STI) clinics.
Participants: 2441 women aged 15–64 years who
participated in the NCSP and 2172 women who attended
two London STI clinics over a 4-month period in 2009.
Outcome measures: (1)M genitalium prevalence in
defined populations (%). (2) Age-adjusted ORs (aORs)
for correlates of M genitalium infection.
Results: The overall frequency of M genitalium and
Chlamydia trachomatis was 3% and 5.4%, respectively.
Co-infection was relatively uncommon (0.5% of all
women); however 9% of women with C trachomatis also
had M genitalium infection. M genitalium was more
frequently detected in swab than urine samples (3.9 vs
1.3%, p<0.001) with a significantly higher mean bacterial
load (p≤ 0.001). Among NCSP participants, M
genitalium was significantly more likely to be diagnosed
in women of black/black British ethnicity (aOR 2.3, 95%
CI 1.2 to 4.5, p=0.01). M genitalium and C trachomatis
and were both significantly associated with multiple
sexual partners in the past year (aOR 2.4, 95% CI 1.3 to
4.4, p=0.01 and aOR 2.0, 95% CI 1.4 to 2.8, p<0.01).
Among STI clinic attendees, M genitalium was more
common in women who were less than 25 years in age.
Conclusions: M genitalium is a relatively common
infection among young women in London. It is
significantly more likely to be detected in vulvovaginal
swabs than in urine samples. Co-infection with
Chlamydia is uncommon. The clinical effectiveness of
testing and treatment strategies for M genitalium needs
further investigation.
INTRODUCTION
Pelvic inﬂammatory disease (PID) and its
sequelae (chronic pelvic pain, ectopic preg-
nancy and tubal infertility) are major causes
of morbidity in women in developed and
developing countries.1 In the USA more
than $10 billion is spent annually in treating
these conditions.2 Chlamydia trachomatis and
Neisseria gonorrhoeae, two sexually transmitted
infections (STIs) are known causes of PID.
However, in up to 70% of PID cases no cause
is found3 and there is increasing evidence
that Mycoplasma genitalium might be a cause
of PID.4–8
There is also strong evidence that it is sexu-
ally transmitted.5 6 It is signiﬁcantly associated
with endometritis and9 tubal factor infertility10
although the association with cervicitis is
complex.11 12 As with C trachomatis it can be
asymptomatic, acting as a reservoir for further
spread.13 It may also be associated with HIV
acquisition.14
Although at present M genitalium is not rou-
tinely tested for in most countries, there is inter-
est in introducing testing and treatment.
However, before this is done there is a need to
gain a better understanding of the infection to
avoid repeating the problems encountered with
C trachomatis screening.15 In the UK there are
few data on the frequency of M genitalium infec-
tion in different population groups of women.
Oakeshott et al16 found that M genitalium
Strengths and limitations of this study
▪ This is the largest UK based-cross-sectional
study to date to provide estimates of
Mycoplasma genitalium prevalence in both com-
munity and sexually transmitted infection clinic-
based populations.
▪ M genitalium PCR results were confirmed posi-
tive by genotype sequencing.
▪ Our analysis of potential correlates for M genita-
lium and Chlamydia trachomatis is limited by the
availability of data.
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prevalence was 3.3% among young women in a community
based sample who took part in a C trachomatis screening
trial in the UK. Estimates from studies in other countries
indicate that levels of M genitalium are 40–60% lower than
C trachomatis, with little co-infection.17 18 The recommended
treatment for uncomplicated Chlamydia infection is a
single dose of azithromycin 1 g stat. There is growing evi-
dence of considerably lower M genitalium cure rates with
this dose of azithromycin compared with C trachomatis
(79–87% vs 92–97%, respectively).19–21 Resistance has been
shown to develop following 1 g of azithromycin and macro-
lide resistance is endemic in some populations.22–24
We investigated M genitalium infection by real-time
PCR and determined its correlates in the largest cross-
sectional study of M genitalium among women screened
for C trachomatis in the National Chlamydia Screening
Programme (NCSP) and STI clinics in the UK.
METHODS
Patients and specimens
We used an unlinked anonymised method to test routinely
collected and stored cervical swabs, self-taken vaginal
swabs and ﬁrst catch urine samples for M genitalium. The
samples were from 2180 women aged 15–64 years who had
C trachomatis screening when they attended two STI clinics
in central and North London and 2455 women aged 15–
24 years who participated in the NCSP in London in a
4-month period in 2009. Each clinic offers comprehensive
STI screening, treatment and partner notiﬁcation services
to symptomatic and asymptomatic women and men, irre-
spective of age. Samples from all female clinic attendees
were eligible for the study. The NCSP is a national screen-
ing programme for Chlamydia in the UK among women
and men who are under 25 years in age. The NCSP
samples were from a variety of low and high STI risk set-
tings within two London boroughs. In 2009 the majority of
participating sites from which the samples were tested
were family planning clinics (47%), universities (17%)
and general practices (16%). Other testing sites included
pharmacies, abortion services, outreach, young persons’
services, schools and postal testing (Tina Sharp, NCSP
Chlamydia Coordinator, personal communication).
The samples were originally collected from the NCSP
and clinics and transported to the Microbiology
Laboratory at University College London Hospital in
3 mL (self-taken vaginal and cervical swabs) or 4 mL
(urine samples diluted 1 : 1) of APTIMA transport
medium (Gen-Probe Inc, San Diego, USA) for routine
C trachomatis testing. After C trachomatis testing the nega-
tive samples were stored for 6 weeks at −20°C and posi-
tive samples were stored for 3 months at −20°C before
they were released for testing as part of this study.
Available demographic, sexual behaviour, clinical PID
diagnosis and STIs data were recorded before samples
were unlinked from all personal identiﬁers prior to
M genitalium testing.
M genitalium testing
Samples were thawed and DNA from 200 µL of the
APTIMA transport medium was puriﬁed by BioRobot
9604 automated workstation using the QIAamp Virus
BioRobot 9604 Kit (QIAGEN, Hilden, Germany). Before
freezing and storing the eluate at −20°C it was tested by
quantitative PCR (qPCR) adapted from a method by
Jensen et al.17 25 The qPCR targeted the MgPa adhesion
gene (MG191) using MgPa-355FW and MgPa-432R
primers and MgPa-380 MGB probe (primers and probes
were provided by Applied Biosystems, Warrington, UK).
Pilot laboratory work showed no difference in APTIMA
Urine Specimen Transport Tubes and APTIMA Vaginal
Swab Specimen Collection Kit transport medium and
phosphate-buffered saline (PBS) spiked with M genitalium
DNA in different concentrations.
We introduced a degenerate oligonucleotide (‘wobble’)
in the forward primer to account for a frequent detected
base substitution that has previously been shown to be suc-
cessful in another study by Chalker et al.26 As an internal
control for PCR inhibition we used murine cytomegalo-
virus (mCMV) and primers mCMVTAQ1 (forward
primer) and mCMVTAQ2 (reverse primer) and
mCMVTAQPR probe labelled with JOE (Primers and
probe were provided by Euroﬁns MWG Operon) designed
by Garson et al.27 The qPCR assays were performed in
25 µL volumes; comprising 1× EXPRESS qPCR Supermix
(Universal, Invitrogen, Life technologies Ltd Paisley, UK),
0.4 µM forward and reverse primers, 0.2 µM probes and
7.5 µL of samples and nuclease-free water (Promega UK
Ltd, Southampton, UK).
Thermal cycling was performed on an ABI 7500
Real-time PCR instrument using the following conditions:
hotstart at 95°C for 2 min and 1 cycle, denaturation at 95°
C for 15 s, annealing and extension at 60°C for 1 min and
45 cycles. The data was analysed using Sequence Detection
Software (SDS) V.1.4 with manual baseline/threshold set-
tings to estimate quantiﬁcation cycle.
Positive samples were re-extracted and retested by
qPCR. If these tested negative the samples were
re-extracted and tested by qPCR a third time. If negative
again the sample was considered equivocal and was
excluded from the analysis.
M genitalium genotyping
M genitalium PCR-positive samples were sequenced by
MgPa1–3 typing assay according to Hjort et al.28 The
assay was modiﬁed with respect to PCR reagents and
PCR conditions. In a total volume of 50 µL the following
were mixed: 25 µL of Taq PCR Master Mix kit
(QIAGEN, Hilden, Germany), 0.4 µM of mgpa-1 and
mgpa-3 primers, 5 µL of template and nuclease-free
water. To increase the sensitivity of the assay 10 µL of the
template was used in cases where the bacterial load was
less than 1 genome copy/µL.
The PCR was performed on an ABI9700 instrument
and in three-step cycling conditions: denaturation at 94°
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C for 1 min, annealing at 60°C for 1 min and extension
at 72°C for 1 min and 50 cycles.
The ampliﬁed product were puriﬁed manually by
QIAquick PCR puriﬁcation kit (QIAGEN, Hilden,
Germany) and sent to the UCL sequencing service for
sequencing of both the forward and reverse strand.
Statistical analysis
We have only included data from women who are at
least 15 years old in the analysis. Data were analysed
using SPSS V.14.0 for Windows. Paired sample t test was
used to compare the difference of mean values. Multiple
logistic regression analysis was used to investigate the
relationship between M genitalium or C trachomatis infec-
tion and demographic and sexual behaviour character-
istics in women attending NCSP or STI clinics.
Categorical variables in the NCSP model included par-
ticipant age, specimen type, a new sexual partner within
3 months, more than one partner within 12 months and
ethnicity. The categorical variables included in the STI
model were participant age, specimen type, current STI
infections and ethnicity. Frequency, ORs adjusted for
age (aOR) and 95% CIs were calculated and values of
p<0.05 were considered statistically signiﬁcant.
RESULTS
Of 4635 samples, we excluded 21 samples for which the
M genitalium test result was equivocal and included 4613
samples in our analysis (ﬁgure 1).
NCSP participants were aged 15–24 years whereas STI
clinic attendees were aged 15–64 years. Women attend-
ing the two clinics had signiﬁcantly different mean ages
(20.1 years, SD 2.5 vs 27.8 years, SD 7.6 years, p<0.0001).
The highest prevalence of M genitalium and C trachomatis
was in age groups 15–24 years in NCSP and the STI
clinics. As we only had ethnicity data for 39% (851/
2172) of the STI clinic attendees, we did not compare
ethnicity across the clinics.
M genitalium and C trachomatis infection
As shown in table 1, the overall frequency of M genita-
lium and C trachomatis was 3% (138/4613, 95% CI 2.5%
to 3.5%) and 5.4% (249/4613, 95% CI 4.8% to 6.1%),
respectively. The overall co-infection rate was 0.5% (23/
4613, 95% CI 0.3% to 0.7%). Of 249 women with
C trachomatis, 23 (9%) women had M genitalium
infection.
Among NCSP participants, M genitalium and C tracho-
matis frequency were 2.3% (57/2441, 95% CI 1.7% to
2.9%) and 6.8% (166/2441, 95% CI 5.8% to 7.8%),
respectively.
M genitalium infection signiﬁcantly differed between the
two clinics (5.3%, 95% CI 3.7% to 7.0% and 3.0%, 95% CI
2.1% to 3.8%, p<0.01) but the difference was not signiﬁ-
cant after adjusting for age (p=0.16). C trachomatis did not
differ signiﬁcantly between the two clinics (3.2%, 95% CI
1.9% to 4.5% and 4.1%, 95% CI 3.1% to 5.1%, p=0.30).
Association of M genitalium and C trachomatis with
sexual behaviour and demographic characteristics
of participants in the NCSP
Table 2 shows the association of M genitalium and C trachoma-
tis with sexual behaviour and demographic characteristics
among NCSP participants. M genitalium was less frequently
detected than C trachomatis in both age groups (15–19 years
old 2.8%, 29/1045 vs 8.3%, 83/1045 and 20–24 years old
2.0%, 28/1396 vs 5.7%, 79/1396, respectively). When
adjusted for ageM genitalium was signiﬁcantly more common
in black/black British women compared with white women
(aOR 2.3, 95% CI 1.2 to 4.5, p=0.01). Women who reported
multiple sexual partners in the past 12 months were twice as
likely to have both M genitalium and C trachomatis infections
compared with women who reported only one partner (aOR
2.4, 95% CI 1.3 to 4.4, p=0.01) and (aOR 2.0, 95% CI 1.4 to
2.8, p<0.01), respectively. Women who reported new sexual
partners in the previous 3 months were also more likely to
have C trachomatis infection (aOR 1.6, 95% CI 1.1 to 2.3,
p=0.01). Those who did not self-identify as white, black/black
British, Asian/Asian British or mixed ethnicity were less likely
to be infected with C trachomatis compared with white
women (aOR 0.6, 95% CI 0.4 to 0.9, p=0.01).
Association of M genitalium and C trachomatis with
sexual behaviour and demographic characteristics of STI
clinic attendees
Table 3 shows the association of M genitalium and C tra-
chomatis with sexual behaviour and demographic
characteristics among STI clinic attendees. The age
Figure 1 Of 4635 samples, 21
samples were excluded for which
the M genitalium test result was
equivocal and 4613 samples
were included in the analysis.
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distribution for both M genitalium and C trachomatis was
similar with infections more frequently detected in
younger women (15–19 years 9.7%, 18/186 vs 6.4%, 12/
186, respectively and 20–24 years 6.2%, 41/665 vs 6.0%,
40/665) than other age groups. M genitalium was more
frequently detected in 15–19 year-old women than C tra-
chomatis although this was not statistically signiﬁcant
(p=0.28).
Specimen type and bacterial load
Overall M genitalium was detected in 3.7% (43/1161),
4.0% (74/1817) and 1.3% (21/1635) of cervical swabs,
self-taken vulval swabs and ﬁrst-void urine samples, respect-
ively. Since M genitalium frequency in cervical and self-
taken swabs was similar (p=0.86), the results for the two
groups of swabs were merged and tested against ﬁrst-void
urine samples in the statistical model. M genitalium was
Table 1 Mycoplasma genitalium and Chlamydia trachomatis infection among NCSP and STI clinic attendees
Infection
Clinic 2 N=716 Clinic 1 N=1456 NCSP N=2441 Total N=4613
N (%, 95% CI) N (%, 95% CI) N (%, 95% CI) N (%, 95% CI)
M genitalium and C trachomatis 3 (0.4, 0 to 0.9) 4 (0.3, 0 to 0.6) 16 (0.7, 0.4 to 1.0) 23 (0.5, 0.3 to 0.7)
Total M genitalium 38 (5.3, 3.7 to 7.0) 43 (3.0, 2.0 to 3.9) 57 (2.3, 1.7 to 2.9) 138 (3.0, 2.5 to 3.5)
M genitalium only 35 (4.9, 3.3 to 6.5) 41 (2.8, 2.0 to 3.7) 39 (1.6, 1.1 to 2.1) 115 (2.5, 2.0 to 2.9)
Total C trachomatis 23 (3.2, 1.9 to 4.5) 60 (4.1, 3.1 to 5.1) 166 (6.8, 5.8 to 7.8) 249 (5.4, 4.8 to 6.1)
C trachomatis only 20 (2.8, 1.6 to 4.0) 56 (3.8, 2.9 to 4.8) 150 (6.1, 5.2 to 7.1) 226 (4.9, 4.3 to 5.5)
NCSP, National Chlamydia Screening Programme; M genitalium, Mycoplasma genitalium; C trachomatis, Chlamydia trachomatis; STI,
sexually transmitted infection.
Table 2 Association of characteristics with Mycoplasma genitalium and Chlamydia trachomatis in NCSP attendees
Characteristic
(N=2441) Per
centage of
women with
characteristic
M genitalium
(%) (proportion
of women) aOR* (95% CI) p Value
C trachomatis
(%) (proportion
of women)
aOR*
(95% CI) p Value
Age
15–19 41.6 2.8 (29/1045) 8.3 (87/1045)
20–24 56.5 2.0 (28/1396) 5.7 (79/1396)
Ethnicity
White 46.6 2.0 (23/1138) 1 7.4 (84/1138) 1
Black or
black British
12.8 4.8 (15/314) 2.3 (1.2 to 4.5) 0.01 8.3 (26/314) 1.1 (0.7 to 1.7) 0.83
Asian or
Asian British
4.4 1.9 (2/108) 0.9 (0.2 to 4.0) 0.93 6.2 (5/108) 0.6 (0.3 to 1.6) 0.33
Mixed 7.7 3.7 (7/187) 1.8 (0.8 to 4.3) 0.18 10.2 (19/187) 1.3 (0.8 to 2.3) 0.29
Other ethnic
groups
28.4 1.4 (10/694) 0.7 (0.3 to 1.5) 0.35 4.6 (32/694) 0.6 (0.4 to 0.9) 0.01
New sexual partner in previous 3 months
Yes 31.5 3.2 (25/770) 1.5 (0.8 to 2.6) 0.20 9.2 (71/770) 1.6 (1.1 to 2.3) 0.01
No 39.3 2.2 (21/959) 1 5.8 (56/959) 1
Do not want
to answer
0.2 0.0 (0/6) – – 0.0 (0/6) – –
Not filled in 28.9 1.6 (11/706) 0.7 (0.3 to 1.4) 0.33 5.5 (39/706) 0.9 (0.6 to 1.4) 0.69
Sex with >1 partner within 12 months
Yes 30.8 3.9 (29/751) 2.4 (1.3 to 4.4) 0.01 10.0 (75/751) 2.0 (1.4 to 2.8) <0.01
No 39.5 1.7 (16/963) 1 5.4 (52/963) 1
Do not want
to answer
0.3 0.0 (0/8) – – 0.0 (0/8) – –
Not filled in 29.5 1.7 (12/719) 1.0 (0.5 to 2.1) 0.99 5.4 (39/719) 1.0 (0.6 to 1.5) 0.99
Specimen
Cervical/ 1.3 3.2 (1/31) 3.3 (0.4 to 25.8) 0.26 9.7 (3/31) 2.0 (0.6 to 7.4) 0.21
Self-taken
vaginal
40.4 4.2 (41/986) 4.2 (2.3 to 7.6) <0.001 9.3 (92/986) 2.0 (1.5 to 2.8) <0.001
First catch
urine
58.3 1.0 (15/1424) 1 5.0 (71/1424) 1
*aOR, ORs adjusted for age only.
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signiﬁcantly more likely to be detected in swabs compared
with urine specimens (3.9 vs 1.3%, p<0.001).
The overall frequency of C trachomatis in cervical
swabs, self-taken vulval swabs and ﬁrst-void urine samples
was 3.5% (41/1161), 7.0% (128/1817) and 4.9% (80/
1635), respectively. C trachomatis signiﬁcantly differed
between cervical and self-taken swabs (p<0.001) and the
two groups were separately tested against the urine
samples in the statistical model.
The majority (58%, 1424/2441) of specimens provided
by the women in NCSP were urine samples. However,
swab samples were almost four times more likely to test
positive for M genitalium compared with urine samples
(aOR 3.6, 95% CI 1.9 to 6.7, p<0.001) and C trachomatis
infection was almost twice as high among swabs com-
pared with urine samples (aOR 1.8, 95% CI 1.2 to 2.4
p=0.001). Conversely the majority (90.3%, 1961/2172) of
clinic specimens were swabs. M genitalium and C trachoma-
tis in the clinic swab and urine specimens also differed
(M genitalium 3.8%, 75/1961 vs 2.8%, 6/211 and C tracho-
matis 3.8%, 74/1961 vs 4.3%, 9/211, respectively).
In quantitative analysis of M genitalium positive speci-
mens, mean M genitalium bacterial load in swab and
urine samples did not signiﬁcantly differ between the
clinics or NCSP. Clinical data were therefore combined
for comparison of the mean bacterial load in different
specimen types. There was no difference in overall cer-
vical and self-taken vaginal swab bacterial loads (3.72 (CI
3.39 to 4.05) vs 3.91 (CI 3.66 to 4.17) log10 genome
copies/mL, equivalent to geometric means of 5218 (CI
2438 to 11 171) and 8192 (CI 4575 to 14 669) organ-
isms/mL, respectively; p=0.349). The overall mean bac-
terial load in swabs 3.84 (CI 3.52 to 4.11) equivalent to
6705 (CI 3506 to 12 920) organisms/mL was signiﬁ-
cantly higher than in ﬁrst-void urine samples (3.14 (CI
2.87 to 3.41) equivalent to 1386 (CI 740 to 2597) organ-
isms/mL) (p<0.0001, equal variances not assumed).
Genetic diversity
The absence of false-positive results was conﬁrmed by
the presence of 57 different genotypes by sequence ana-
lysis of 127 M genitalium-positive specimens and 13
sequences from previously isolated strains (ﬁgure 2).
The discriminatory index by Hunter and Gaston29 was
calculated to be 0.94 both with and without inclusion of
the previously isolated strain sequences. None of the
sequenced samples were identical with the type strain
G37 used as a PCR standard control. Genetic diversity
data are available in FASTA format for download in the
online supplementary material.
DISCUSSION
Overall M genitalium was relatively common at 3%
among NCSP participants and STI clinical attendees. M
genitalium was more likely to be found in swabs
Table 3 Association of characteristics with Mycoplasma genitalium and Chlamydia trachomatis in women attending two
London STI clinics
Characteristic
(N=2172)
Percentage of
women with
characteristic
M genitalium
(%) (proportion
of women)
aOR*
(95% CI) p Value
C trachomatis
proportion of
women)
aOR*
(95% CI) p Value
Age
15–19 8.6 9.7 (18/186) 6.4 (12/186)
20–24 30.6 6.2 (41/665) 6.0 (40/665)
25–29 28.6 1.6 (10/621) 2.9 (18/621)
30–34 15.6 2.3 (9/339) 3.2 (11/339)
35–64 16.6 0.8 (3/361) 0.6 (2/361)
Ethnicity
White 23.0 6.0 (30/499) 1 7.0 (35/499) 1
Black or
black British
6.9 7.4 (11/149) 1.2 (0.6 to 2.5) 0.60 4.0 (6/149) 0.5 (0.2 to 1.3) 0.54
Asian or
Asian British
1.7 17.6 (6/36) 3.1 (1.2 to 8.1) 0.19 5.6 (2/36) 0.8 (0.2 to 3.4) 0.73
Mixed 3.9 4.8 (4/84) 0.7 (0.2 to 2.1) 0.54 7.1 (6/84) 0.9 (0.4 to 2.3) 0.91
Other Ethnic
groups
3.9 9.5 (8/83) 1.6 (0.7 to 3.7) 0.24 3.6 (3/83) 0.5 (0.1 to 1.6) 0.49
Unknown 60.8 1.7 (22/1321) 0.5 (0.2 to 1.1) 0.09 2.3 (31/1321) 0.7 (0.3 to 1.4) 0.66
Specimen
Cervical/ 90.3 3.8 (75/1961) 1.4 (0.6 to 3.2) 0.48 3.4 (38/1130) 0.7 (0.4 to 1.6) 0.44
Self-taken
vaginal
4.3 (36/831) 0.9 (0.4 to 2.0) 0.83
First catch
urine
9.7 2.8 (6/211) 1 4.3 (9/211) 1
*aOR, ORs adjusted for age only.
STI, sexually transmitted infection.
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compared with urine samples (3.9% vs 1.3%, respect-
ively) and the mean bacterial load was also much higher
(6705 (CI 3506 to 12 920) organisms/mL vs 1386 (CI
740 to 2597) organisms/mL, respectively).
Only 0.5% of all the women had both C trachomatis
and M genitalium infections. Among women who had
C trachomatis, 9% were coinfected with M genitalium com-
pared with <5% in population-based studies.16 18 30 31
Among NCSP participants the age-adjusted odds of
detecting M genitalium were twice as high among women
of black/black British ethnicity (aOR 2.3) and those
reporting multiple sexual partners in the past year (aOR
2.4) compared with women of white ethnicity or those
who reported only one partner, respectively. After adjust-
ing for age, C trachomatis was also signiﬁcantly more
likely to be diagnosed in women with multiple partners
(aOR 2.0) and new sexual partners in the previous
3 months (aOR 1.6) but was less likely to be detected in
women who did not give a self-identiﬁed ethnic group
(aOR 0.6) compared with reporting only one partner,
not reporting new partners or being of white ethnicity,
respectively. No signiﬁcant associations were observed
for either infection among STI clinical attendees.
This is the largest UK-based M genitalium study to date
to provide estimates of infection among both commu-
nity and STI clinic-based populations. Transport media
may affect the sensitivity of DNA-based PCR tests. The
study samples were originally collected in APTIMA
medium. We, therefore, tested APTIMA and PBS media
with M genitalium DNA and did not ﬁnd any differences.
We conﬁrmed positive M genitalium PCR results by geno-
type sequencing. Our analysis of M genitalium and C tra-
chomatis correlates is limited by availability of data: only
age and ethnicity were available for both clinical and
NCSP datasets and ethnicity data was missing for 61% of
STI clinical attendees. There is also a possibility that
Figure 2 Phylogenetic tree showing clustering of 127 DNA sequences from the Mycoplasma genitalium-positive specimens of
the study (marked with grey font) and 13 DNA sequences from M genitalium strain from patients with no known sexual
relationship (marked with black font).
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some young women may have had Chlamydia tests
through both the NCSP and the STI clinics during the
sample collection period. It is not possible to quantify
this although we speculate that the numbers are likely to
be low given the relatively short time frame.
Our STI clinical M genitalium frequency is similar to
that found in several studies of female STI clinical atten-
dees (4.5–7%)32 33 although other studies have reported
much higher frequencies (19.3–38.2%).12 34 In lower
risk non-STI clinical attendees such as college students
infection has been shown to range from <1% to 5%5 35
which is in keeping with our estimate in the Chlamydia
screening population. The higher frequency of M genita-
lium in women attending clinics than the NCSP (3–5.3%
vs 2.3%, respectively) may in part reﬂect the higher pro-
portion of swabs taken in clinics than in NCSP settings.
Urine samples have been shown to be less sensitive for
M genitalium diagnosis than swabs (61–65% compared
with 74–91%).36 37 It is therefore likely that our NCSP M
genitalium frequency is an underestimation. Although
urine sample sensitivity may be increased by
up-concentrating the samples by centrifugation this is
not a practical step for large scale testing. A higher bac-
terial load may be associated with symptoms as has been
shown for men.25 This may also explain the difference
in infection between the two populations since STI clin-
ical attendees are more likely to be symptomatic than
NCSP participants. The association of M genitalium with
multiple sexual partners and black ethnicity has been
previously observed.16 31 Additional risk factors include
younger age as observed in our STI clinical attendees,
bacterial vaginosis, being symptomatic, cervicitis, douch-
ing, smoking, prior miscarriage, menstrual cycle, social
class and marital status.12 16 31 38–40
M genitalium appears to be a relatively common infection
among women in London. The low level of M genitalium
and C trachomatis co-infection (0.5%) suggests that diag-
nosing and treating Chlamydia will have little impact on
M genitalium. However, azithromycin 1 g used to treat
uncomplicated C trachomatis infection appears to be sub-
optimal for M genitalium treatment.24 This treatment dose
has also been associated with the development of M genita-
lium macrolide resistance in some studies of predomin-
antly symptomatic men.22 24 The risk of inadvertent M
genitalium antibiotic resistance in coinfected women who
are treated for Chlamydia with 1 g of azithromycin is there-
fore potentially a cause for concern although further
research is required to conﬁrm this.
To avoid the problems encountered with C trachomatis
screening and M genitalium antimicrobial resistance, prior
to introducing routine testing for M genitalium, further
research is needed to better understand its natural history,
the role of asymptomatic and symptomatic M genitalium in
PID and determine optimum treatment guidelines.
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